X4 Pharmaceuticals, Inc.
A Boston-based biopharmaceutical company that makes medicines for rare immune-system diseases. Its drug XOLREMDI (mavorixafor), an oral pill approved by the FDA, treats WHIM syndrome, an ultra-rare inherited disorder that traps infection-fighting white blood cells in the bone marrow. Founded around 2015, the company took its name from the CXCR4 receptor its drug targets, and it built its lead medicine from a molecule originally developed by Sanofi.
Granted 3.70M · Sold 836.5K
Granted 1.30M · Sold 224.3K
Granted 875.8K · Sold 11.6K
Granted 1.49M · Sold 762.0K
Granted 558.3K · Sold 177.4K
Granted 289.9K · Bought 86.2K
Granted 289.9K
Granted 193.3K · Sold 17.0K
Granted 105.0K · Sold 32.6K
Granted 97.0K · Sold 928
Granted 96.7K
Granted 96.7K
Granted 745.7K · Bought 35.0K · Sold 50.5K
Granted 323.1K · Sold 130.1K
Granted 3.3K
Granted 136.5K
Granted 98.2K · Bought 25.0K
Granted 98.2K
Granted 98.2K
Granted 98.2K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Ragan PaulaPresident and CEO, Director · 23 transactions | +611.6% | 3.34Mas of Feb 2025 | 3.70M | — | 836.5K |
| DiBiase MaryChief Operating Officer · 23 transactions | — | 1.14Mas of Feb 2025 | 1.30M | — | 224.3K |
| Arbet-Engels ChristopheChief Medical Officer · 3 transactions | — | 864.2Kas of Feb 2025 | 875.8K | — | 11.6K |
| Mostafa Adam S.Chief Financial Officer · 20 transactions | +602.8% | 850.0Kas of Feb 2025 | 1.49M | — | 762.0K |
| Taveras ArthurChief Scientific Officer · 10 transactions | +4729.2% | 388.0Kas of Oct 2024 | 558.3K | — | 177.4K |
| Craig Adam RExecutive Chairman, Director · 2 transactions | — | 376.1K | 289.9K | 86.2K | — |
| Volpone JohnPresident · 1 transaction | — | 289.9Kas of Aug 2025 | 289.9K | — | — |
| Kirske DavidChief Financial Officer · 2 transactions | — | 176.3K | 193.3K | — | 17.0K |
| Meisner Derek MChief Legal Officer · 5 transactions | +99.6% | 145.2Kas of Aug 2022 | 105.0K | — | 32.6K |
| Cadavid DiegoChief Medical Officer · 2 transactions | +1195.7% | 104.1Kas of Mar 2022 | 97.0K | — | 928 |
| Aliski WilliamDirector · 3 transactions | — | 96.7Kas of Jun 2024 | 96.7K | — | — |
| Lawton Alison FrancesDirector · 3 transactions | +853.9% | 96.7Kas of Jun 2024 | 96.7K | — | — |
| Baldry MarkChief Commercial Officer · 10 transactions | — | 25.3Kas of May 2025 | 745.7K | 35.0K | 50.5K |
| Stewart MurrayDirector · 5 transactions | — | 7.9Kas of Jun 2025 | 323.1K | — | 130.1K |
| Thoren Natasha FayChief Legal Officer · 1 transaction | — | 7.0Kas of Jun 2025 | 3.3K | — | — |
| Woods KeithDirector · 3 transactions | — | 6.0Kas of Jun 2025 | 136.5K | — | — |
| Wyzga Michael SDirector · 5 transactions | — | 5.6Kas of Jun 2025 | 98.2K | 25.0K | — |
| Bridger GaryDirector · 4 transactions | — | 4.7Kas of Jun 2025 | 98.2K | — | — |
| McGirr David W JDirector · 4 transactions | — | 4.7Kas of Jun 2025 | 98.2K | — | — |
| de Craecker FrancoiseDirector · 4 transactions | — | 4.7Kas of Jun 2025 | 98.2K | — | — |
Select a row to see that insider’s individual transactions.
Net open-market activity over the last 5 years: -2.10M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.